))
051: Ada Le and Mousumi Sannigrahi on behavioural science in healthcare
Manage episode 404797533 series 3556050
Contenu fourni par Daniel Ross and Dan Biggar, Daniel Ross, and Dan Biggar. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Daniel Ross and Dan Biggar, Daniel Ross, and Dan Biggar ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
This week we’re diving into healthcare; what could be more critical? To help me understand how behavioural science is impacting this field, I’m joined by Dr. Ada Le, healthcare expert at BEworks and Dr. Mousumi Sannigrahi, newly installed as Head of Commercial for Innovative Medicines at Fosun Pharma US, having spent the last 8 years at Novartis Pharma.
Show notes
- What’s happening at the intersection of behavioural science and the pharma industry?
- How behavioural science plays out at Fosun vs. Novartis
- The next frontier for healthcare and behavioural science
- What needs to happen to move to a more human-centric approach to healthcare?
- The goal of the 1% Steps for Health Care Reform Project
- What are easy wins that the pharma industry can enact now?
- Psychological barriers for patients with autoimmune disease
- Rosy retrospection bias and failure to prescribe the right treatment
- David Robson and expectation effects: how mindset can alter our lives
- Dan Ariely’s end of life theories and research
- The scientific method of problem solving vs. more subtle placebo effects
- Hopes for healthcare in the next year
Please leave a review if you like the podcast; and share with friends. Your support makes us very happy!
85 episodes
Partager
